Form 4: VolitionRx CEO Singapore, Jasmine Kway, Reports Acquisition of 13,570 Shares of Common Stock

Jasmine Kway, CEO Singapore of VolitionRx Ltd, reports acquiring 13,570 shares of common stock on June 1, 2024, through restricted stock units (RSUs) in lieu of cash compensation.

Summary

• On June 4, 2024, Jasmine Kway, CEO Singapore of VolitionRx Ltd, filed a Form 4 with the SEC.
• The report details the acquisition of 13,570 shares of common stock on June 1, 2024.
• These shares were acquired through restricted stock units (RSUs) under the Issuer's 2015 Stock Incentive Plan.
• The RSUs were awarded in lieu of cash compensation.
• The RSUs vest in three installments of 4,524 units, 4,523 units, and 4,523 units on June 1, 2024, July 1, 2024 and August 1, 2024, respectively.
• The RSUs are also subject to further time-based vesting in a single installment on May 1, 2025.
• Kway also indirectly owns 10,400 shares through a spouse.
• Following the reported transaction, Kway directly owns 118,485 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The CEO acquiring shares, even as part of compensation, is generally a good sign, indicating confidence in the company. However, it's not a market purchase, so the impact is limited.

Positives

• The acquisition of shares by the CEO demonstrates confidence in the company's future.

Industry Context

Insider transactions are closely monitored as they can provide insights into management's perspective on the company's prospects. This transaction reflects the compensation structure for VolitionRx executives.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholder sentiment.

Key Dates